Navigation Links
Archimedes Pharma Announces Successful Proof-of-Concept Results on Two Intranasal Development Projects
Date:2/26/2009

uce fast, effective and convenient treatment for breakthrough cancer pain. Results from Phase III trails show NasalFent to have class-leading characteristics. This product, which has blockbuster potential, is targeted for launch in 2010 and Archimedes will market it through its own sales teams in Western Europe. Archimedes' other pipeline products include intranasal Apomorphine for advanced Parkinson's disease and intranasal Diazepam for acute repetitive seizures.

Archimedes technologies - ChiSys(R), PecSys and TARGIT(R) - are also used in a number of partnered products in late-stage clinical development. Additionally, Archimedes' innovative drug delivery technology has proven potential for vaccine delivery with pre-clinical and clinical studies of nasally administered vaccines demonstrating enhanced immune response.

Archimedes marketed products include Gliadel, a biodegradable wafer impregnated with an anti-cancer drug, carmustine, for high-grade glioma; Zomorph and Oramorph both morphine products for pain; and Pabrinex, a high potency vitamin formulation used to treat the symptoms of malnutrition especially in patients with acute alcohol problems.

Archimedes Pharma is UK based, with offices in Reading and development facilities in Nottingham. Further European commercial operations are established in Ireland, France and Germany. The Company was founded in December 2004 and is backed by Warburg Pincus, a leading private equity investor with extensive experience in the healthcare sector. In 2008, Archimedes had sales of GBP20.4 million.

Enquiries

Archimedes Pharma: Michael Clark, +44-118-931-5050

Citigate Dewe Rogerson: Chris Gardner/Heather Keohane, +44-207-638-9571 (media enquiries)

Trout International LLC: Mike Booth, +44-20-7936-9326 (investor enquiries)

For more information on Archimedes, visit:

SOURCE Archimedes Pharma Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Adlyfe Strikes Translational Medicine Partnership With Wyeth Pharmaceuticals for Alzheimers Biomarker Assay
2. MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints
3. AstraZenecas Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
4. Cordex Pharma Announces Strategic Master Services Equity Agreement With Cato BioVentures
5. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
6. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
7. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
8. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
9. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
10. Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
11. Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015  Seeger Weiss LLP ... bellwether trial will commence October 13, 2015. ... the 510K fast-track approval program, Zimmer NexGen knee implant ... only requires that companies provide evidence that the product ... in order to gain permissions. In ...
(Date:9/2/2015)... SAN DIEGO , Sept. 2, 2015  Neurocrine ... Tim Coughlin , Chief Financial Officer of Neurocrine ... Conference in New York City . ... September 9 at 11:25am ET (8:25am PT).  The presentation ... Company,s website at http://www.neurocrine.com .   ...
(Date:9/2/2015)... QC , Sept. 2, 2015 Demers Ambulances ... (EEP) Inc. as their new dealer for the states of ... and Tennessee . "This ... customers," said Benoit Lafortune , Executive Vice-President for Demers ... Mississippi and Alabama ...
Breaking Medicine Technology:Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2Demers Ambulances has named Emergency Equipment Professionals (EEP) Inc. as their dealer for the states of MS, AL and TN 2
... Animal Health has launched its second product in the ... milbemycin oxime), a broad-spectrum parasiticide that kills fleas and ... infestations, the prevention of heartworm disease and the treatment ... in dogs and puppies 8 weeks and older, and ...
... 17, 2011 SFA Marketing today announced a ... exclusively to working with medical device manufacturers. SFA ... more than 20 years experience working with clients ... (Logo: http://photos.prnewswire.com/prnh/20110117/NY30375LOGO) "In response ...
Cached Medicine Technology:Elanco Launches Broad-Spectrum Canine Parasiticide 2Elanco Launches Broad-Spectrum Canine Parasiticide 3Elanco Launches Broad-Spectrum Canine Parasiticide 4
(Date:9/2/2015)... ... ... A recent survey by Consumer Reports ( http://bit.ly/1h67tL8 ) sheds light on ... consumers. It was reported that 33% are paying an average of $39 more out-of-pocket ... $100 compared to last year. Among the drugs that saw the highest increases were ...
(Date:9/2/2015)... MN (PRWEB) , ... September 02, 2015 , ... ... commercializing products for the upper extremity surgical market, announced today that more than ... for trigger releases in the hand. Plus, nearly 70 of these procedures ...
(Date:9/2/2015)... ... September 02, 2015 , ... Ovarian cancer continues to be the deadliest of ... ovarian cancer in her lifetime is approximately 1 in 75. This year it is ... 14,000 will die. , There is no test to detect ovarian cancer. A ...
(Date:9/2/2015)... ... ... “ G-Hold ” was featured on NewsWatch as part of its monthly ... Forstrom, a technology expert and special reporter for NewsWatch, conducted the review and shared ... while reducing the likelihood of it dropping. , Tablets like the iPad and Samsung ...
(Date:9/2/2015)... ... September 02, 2015 , ... Please join the world renowned ... which was established by the Foundation in 2007 with the help of Massachusetts ... more research remains our top priority,” commented Christine Buckley, Executive Director of the ...
Breaking Medicine News(10 mins):Health News:Watertree Health President Responds to Consumer Reports Survey on Rising Prescription Drug Prices 2Health News:Trigger Tome Surpasses 600 Successful Patient Procedures 2Health News:National Ovarian Cancer Coalition's DFW Chapter Features First Annual Teal Lights Display This Friday, September 4th, "National Wear Teal Day" 2Health News:National Ovarian Cancer Coalition's DFW Chapter Features First Annual Teal Lights Display This Friday, September 4th, "National Wear Teal Day" 3Health News:Comfortably Hold a Tablet with G-Hold Hands Free Tablet Holder 2Health News:September Celebrated as Brain Aneurysm Awareness Month 2
... ,Renovis, Inc. (Nasdaq: RNVS ), a biopharmaceutical ... for major medical needs in the areas of,neurological ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, ... Trade Commission,requesting additional information with regard to the ...
... a lifetime, researchers say, , , THURSDAY, April 3 (HealthDay News) ... victims of maltreatment in 2006 during their first year of ... their first week of life, federal officials reported Thursday. ... risk for nonfatal maltreatment of children less than 1 year ...
... scientists are the first to observe in living cells a ... of the four building blocks that comprise DNA. Also ... replication. The findings, which will be published in the ... to new cancer treatments that prevent cancer cells from replicating ...
... of health care information to,patients for disease management, ... Today URAC called,for public comment on revisions ... accreditation programs. URAC is seeking input from any,interested ... organizations and health plans. The deadline for public,comment ...
... 2008 ... WHO/ WHAT: "Iron Andy" Holder, an Ironman Arizona competitor who was ... this Sunday,s triathlon to encourage others who have chronic ... condition and to live without limits., ...
... 3, 2008 -- A study led by researchers at Memorial ... a particular type of molecule to promote metastasis -- the ... 90 percent of all cancer-related deaths. The study is published ... work examines how cells in the body communicate with each ...
Cached Medicine News:Health News:Renovis Announces Expiration of Hart-Scott-Rodino (HSR) 30-Day Waiting Period; Merger With Evotec on Track to Close in Early May, 2008 2Health News:Renovis Announces Expiration of Hart-Scott-Rodino (HSR) 30-Day Waiting Period; Merger With Evotec on Track to Close in Early May, 2008 3Health News:Renovis Announces Expiration of Hart-Scott-Rodino (HSR) 30-Day Waiting Period; Merger With Evotec on Track to Close in Early May, 2008 4Health News:More Than 90,000 U.S. Infants Are Victims of Abuse or Neglect 2Health News:More Than 90,000 U.S. Infants Are Victims of Abuse or Neglect 3Health News:Enzyme complex could be key to new cancer treatments 2Health News:URAC Releases Draft Standards for Public Input for Nine Health Care Management Accreditation Programs 2Health News:Ironman Competitor with Diabetes Encourages Others to Live Without Limits; Competes in Ironman Arizona in Tempe 2Health News:Researchers learn how signaling molecule orchestrates breast cancer's spread 2
Alvis foreign body spud 4 3/4 inches, oval curette 1 x 3 mm with fine point....
... is made from MMA/VP material and has a ... is supplied with the base curve and total ... is available in a power range of -30.00DS ... of protective and therapeutic applications including the controlled ...
... soft contact lenses can be used as ... to relieve corneal pain in the treaent ... as bullous keratopathy, corneal erosions, entropion, corneal ... post-surgical conditions resulting from cataract extraction and ...
Cottle-Joseph Double Hook 12 mm wide....
Medicine Products: